Day 1: Wednesday, October 2, 2013
Day 2: Thursday, October 3, 2013
Day 3: Friday, October 4, 2013
Download full program (including pre-congress sessions)
What's the difference between plenary, parallel and workshops?
See session descriptions here.
View full faculty list
| Simultaneous translation into French
|
| Session delivered in French
|
Wednesday, October 2, 2013
Day 1:
Why and how specific
neurons die in Parkinson’s disease and what can be done about it
Plenary Session
Level of talks: Crosstalk
Learning Objectives:
1.
To learn about new mechanisms of neurodegeneration
of PD;
2.
To understand the multifaceted nature of the neurodegenerative
process in PD;
3.
To acquire knowledge as to how basic science may
help in treatment for PD.
Chair: Thomas Gasser
(Germany)
Co-chair: Jon Stamford (UK)
Lecture 1: Propagation of the neurodegenerative process in PD
and the Prion-like hypothesis
Speaker: Virginia Lee (USA)
Lecture 2: Can the interaction between genetics, environment,
and behavior be a key determinant of PD expression
Speaker: Christine Klein (Germany)
Lecture 3: What epidemiological and preclinical studies teach
us about inflammation and PD
Speaker: Etienne Hirsch (France)
Lecture 4: Developing new treatments founded on the basic
science of PD
Speaker: Patrik Brundin (USA)
Special Lecture
Introduction by
Stanley Fahn (USA)
Lecture Title: The Life and Times of James Parkinson
Speaker: Gerald Stern
Lecture Title: The Glory of Canadian Sciences and Parkinson's Disease
Speaker: Rémi Quirion (Canada)
SESSION I -- 1:30PM – 3:00PM
Parallel Session: New genes and risk factors of PD
Level
of talks: Moderately scientific
Learning Objectives:
1.
To learn about new dominant and recessive
high-penetrance PD genes as well as the newly discovered rare variants with
moderate effect and their implication for the understanding of the biology of
neurodegeneration in PD;
2.
To learn about the role of common genetic risk-factors
identified through GWAS, and their biological effects;
3.
To learn about the latest developments that goes
beyond pure genetic analysis and takes into account environmental factors,
epigenetic modifications and clinical endophenotypes.
Chair: Christine Klein (Germany)
Co-chair: Matthew Farrer (Canada)
Lecture 1: New PD genes and rare variants
Speaker: Matthew Farrer (Canada)
Lecture 2: Risk factors for sporadic PD
Speaker: Andrew Singleton (USA)
Lecture 3: Genetics and gene environment interactions
Speaker: Haydeh Payami (USA)
Parallel Session: Protein misfolding as a key pathogenic
event
Level
of talks: Highly scientific
Learning Objectives:
1. To learn about the notion of protein folding and its role in
pathological situations;
2. To understand the importance of the mechanisms responsible for the
maintenance of the well-being of proteins;
3. To acquire knowledge about the link between defects in the lysosomal
function and neurodegeneration.
Chair: Virginia Lee (USA)
Co-chair: Leonidas Stefanis (Greece)
Lecture
1:
Alpha-synuclein conformation and neurodegeneration
Speaker: Leonidas
Stefanis (Greece)
Lecture
2: Protein misfolding in neurodegenerative diseases
Speaker: Leonard Petrucelli
(USA)
Lecture
3:
Link between lysosomal function and neurodegeneration in PD
Speaker: Dimitri Krainc
(USA)
Parallel Session: Role
of functional imaging modalities in the diagnosis and management of PD
Level of talks: Crosstalk
Learning Objectives:
1. Learn about new
advances in structural magnetic resonance (MR) imaging applied to PD, possible
roles for diagnosis, differential diagnosis and biomarker;
2. Learn about
neurochemical imaging using either PET or SPECT, role in diagnosis and as a
biomarker to detect preclinical disease and measure disease progression;
3. Learn how
studies of cerebral connectivity (fMRI, PET, DTI) can enhance our understanding
of PD and of brain function.
Chair: Jon Stoessl (Canada)
Co-Chair: David Eidelberg (USA)
Lecture
1:
Structural imaging for PD: MRI and transcranial sonography (TCS)
Speaker: Klaus Seppi
(Austria)
Lecture
2: Neurochemical imaging
Speaker: Nicola Pavese
(UK)
Lecture
3: Functional connectivity
Speaker: David
Eidelberg (USA)
Parallel Session: Non-dopaminergic systems in PD: Anatomy,
Biochemistry, and Pathology
Level of talks: Moderately scientific
Learning Objectives:
1. Understand how
impairment in serotonin neuron function impacts the development of non-motor
symptoms in PD;
2. Able to describe
how cholinergic neuron dysfunction impacts the development of non-motor symptoms
in PD and related disorders;
3. Explain the role
of glutamatergic and serotonergic neurotransmission for the development of
L-DOPA induced dyskinesias.
Chair: Anders Björklund
(Sweden)
Co-chair: Abdelhamid Benazzouz (France)
Lecture 1: Role of
noradrenaline and serotonin systems for the development of non-motor symptoms
Speaker: Abdelhamid Benazzouz
(France)
Lecture 2: Impact of cholinergic
dysfunction on the development of non-motor symptoms
Speaker: Nicolaas
Bohnen (USA)
Lecture 3: Role of non-dopaminergic
systems in the development of L-DOPA-induced dyskinesias
Speaker: Angela Cenci (Sweden)
Workshop: Why supporting research is crucial: from government to
private funding agencies
Level of talks: Crosstalk
Learning Objectives:
1.To understand the value of basic research in
understanding causes of and finding treatments for PD;
2.To recognize the complementary roles of governmental agencies and
non-governmental organizations in supporting basic research;
3.To provide examples of how the Parkinson’s community can effectively
advocate for research funding.
Introduction: Tom Isaacs (UK)
Panelists: Etienne Hirsch (France), Rémi Quirion
(Canada), Todd Sherer (USA), Amy Comstock Rick (USA)
Workshop: Mitochondrial defect in PD: myth or reality?
Level of talks: Crosstalk
Learning Objectives:
1. To learn about
mitochondrial biology;
2. To understand
the key issues that surrounds the question of mitochondrial defect in PD;
3. To participate
in a discussion about whether or not at this point there are sound experimental
elements to implicate a mitochondrial defect in PD pathogenesis.
Overview: Mitochondria: a
multifunctional organelle
Speaker: Carolyn Sue (Australia)
Case
presentations: The status of mitochondria in PD
Panelists: Carolyn Sue (Australia),
Luca Scorrano (Switzerland) & TBD
Workshop: Sexual issues in Parkinson's disease: assessment and intervention
Level of talks: Crosstalk
Learning Objectives:
1.
Describe the variety of sexual disorders among
patients with Parkinson’s disease;
2.
Appreciate the range of therapeutic interventions
for the various sexual disorders in Parkinson’s disease;
3.
Understand that having Parkinson's disease and
being intimate are not mutually exclusive.
Overview: Sexual challenges in
Parkinson’s and therapeutic options
Speaker:
Paul Rabstyzn (Netherlands)
Case Presentations:
Panelists: Gila Bronner (Israel)
& Paul Rabstyzn (Netherlands)
Workshop: Quality of life and comfort in the late stages of Parkinson's
disease
Level of talks: Crosstalk
Learning Objectives:
1.
Explore the symptoms of late stage and end stage
Parkinson’s;
2.
Understand the medical, ethical and legal issues;3.
Learn about the Palliative Care model, helpful in
maintaining comfort for patient/family.
Overview: Issues and choices in late stage Parkinson’s
Speaker: Janis Miyasaki (Canada)
Case
Presentations
Panelists: Lisa Mann (USA) and Janis Miyasaki (Canada)
French Track
Level
of talks: Crosstalk in French
Chair: Serge Przedborski (USA)
Lecture 1: Is
there a functional defect with mitochondrial in Parkinson’s disease?
Speaker: Miquel Vila (Spain)
Lecture
2: Clinical
Trials: Present challenges and emerging breakthroughs
Speaker: Olivier
Rascol (France)
SESSION II - 3:30PM – 5:00PM
Parallel Session: Quality of life in Parkinson’s disease:
several important determinants
Level of talks: Crosstalk
Learning Objectives
1.
Define obstacles people face after diagnosis
through the continuum of the disease;
2.
Understand practical solutions and methods of
achieving overall quality of life;
3.
Understand the power of engagement and advocacy in
dealing with psychological challenges of PD.
Chair:
Alessandro Di Rocco (USA)
Co-chair: Peter Fletcher (UK)
Lecture
1:
Practical solutions to driving, early job
loss, and relationship issues
Speaker: Peter Fletcher (UK)
Lecture
2:
Psychological solutions to dealing with
pity, dignity, sense of worth and communication
Speaker: Diane Cook (USA)
Lecture 3: Physical solutions to coping with pain,
motor/non-motor, cognition, mood, and behavior
Speaker: Soania Mathur (Canada)
Parallel Session: How Parkinson’s affects attention and
memory
Level
of talks: Crosstalk
Learning Objectives:
1. Describe the clinical features, syndromes,
and proposed mechanisms of cognitive dysfunction in Parkinson’s disease;
2. List and contrast the various approaches for
evaluating and monitoring the progression and treatment of cognitive
dysfunction in Parkinson’s disease, including assessments that can take place
during a clinical interview, using bedside; screening tools, and in
performance-based tests;
3. Initiate practical strategies for management
of cognitive deficits in Parkinson’s disease.
Chair: Alexander Tröster (USA)
Co-Chair: Connie Marras (Canada)
Lecture 1: Memory and attention
issues in Parkinson’s disease—clinical characteristics and mechanisms
Speaker: David Burn (UK)
Lecture
2: Clinical Assessment of Cognition in PD
Speaker: Connie Marras (Canada)
Lecture
3: Practical management of cognitive deficits in Parkinson's disease; what
can occupational therapists offer?
Speaker: Margarita
Makoutonina (Australia)
Parallel Session: Experimental models of non-motor
manifestations of PD
Level
of talks: Moderately scientific
Learning Objectives:
1. Describe animal
models of non-motor manifestation in Parkinson’s disease;
2. Compare the
non-motor symptoms in Parkinson’s disease and animal models;
3. Identify the
neuronal network involved in the genesis of non-motor symptoms in Parkinson’s
disease.
Chair:
Beth-Anne Seiber (USA)
Co-Chair: Ingrid Philippens (Netherlands)
Lecture 1: Animal models of hyper dopaminergic behavior in
Parkinson’s disease
Speaker: Christelle Baunez
Lecture
2: Animal models of sleep disorders in Parkinson’s disease
Speaker:
Ingrid H Philippens (Netherlands)
Lecture
3: Animal models of gastrointestinal dysfunction in Parkinson’s disease
Speaker: Marie-Françoise
Chesselet (USA)
Parallel Session: Optogenetic tools to study PD
pathophysiology
Level of
talks: Highly scientific
Learning
Objectives:
1. To understand
the power and use of Optical Neural Engineering to probe neural function;
2. To describe how
neural activity shapes motor behavior;
3. To be able to
discuss how neural activity controls motor behavior.
Chair: Ted Dawson (USA)
Co-Chair: Antoine Adamantidis (Canada)
Lecture 1: Optical Neural Engineering
Speaker: Antoine Adamantidis (Canada)
Lecture
2: Regulation of Parkinsonian motor behaviors by optogenetic control of
basal ganglia circuitry
Speaker: Anatol Kreitzer (USA)
Lecture 3: Optical Interrogation of
the dopaminergic systems
Speaker:
Antonello
Bonci (USA)
Workshop: Everything you always wanted to know about genetics and that
you never dared to ask
Level
of talks: Crosstalk
Learning Objectives:
1. To understand
the basic principles of Mendelian genetics;
2. To learn about
the genetic contribution to Parkinson’s disease;
3. To recognize the
familial significance of genetics on Parkinsonisms.
Overview: What is
genetics?
Speaker: Carolyn Sue (Australia)
Case Presentations:
Panelists: Susan Bressman
(USA) and Carolyn Sue (Australia)
Workshop: How researchers and people
with Parkinson’s can advance clinical trials together
Level
of talks: Crosstalk
Learning Objectives:
1. To learn about
opportunities where people with Parkinson's can learn about and be trained as
clinical research advocates.
2. To understand
the key issues that people with Parkinson's should be aware of and questions
they should be asking when evaluating a clinical trial and where or not to
participate
3. To understand that
there are steps people with Parkinson's can take to influence and improve the
clinical trial process
Overview:
Speaker: Linda Morgan (USA)
Panel
Discussion:
Panelists: Tom Isaacs (UK, Steve DeWitte (USA) & Linda Morgan (USA)
Workshop: How drugs make it to your cabinet
Level
of talks: Crosstalk
Learning Objectives:
1.
Understand the process of drug discovery and
resources needed to bring drugs to patients’ cabinets
2.
Understand translational research (from the bench
to the bedside);
3.
Be able to explain the pre-clinical and clinical
phases of drugs and the important role of the Parkinson community in pushing
these phases forward.
Overview: Innovations in
neuroscience technologies as they apply to finding target molecules to the
point of pre-clinical studies
Speaker:
Howard
Federoff (USA)
Panel
Discussion:
Panelists:
Baltazar Gomez-Mancilla (Switzerland) and Howard Federoff (USA)
Workshop: Music, art, creativity and Parkinson's
Level of
talks: Crosstalk
Learning
Objectives:
1.
To understand how people with Parkinson’s have
integrated high-quality performing and visual arts into their Parkinson’s
outreach and support programs;
2.
To explore effective common Best Practices in
singing, visual art, and dance programs that have worked particularly well in
engaging persons with PD, care partners and families;
3.
Understand methods and barriers to building
arts-based programs.
Overview: Creativity and Parkinson’s
Speaker: Steven Frucht (USA)
Panel
discussion:
Panelists: Steven Frucht (USA), Margaret
Mullarney (Ireland), David Simmonds (Canada)
French Track
Level of talks: Crosstalk in French
Chair: David
Lussier (Canada)
Lecture 1: Is there a role for gene- and
cell-based therapies in the treatment of Parkinson disease?
Speaker: Stephane Palfi (France)
Lecture 2: Sleep, fatigue and apathy in Parkinson's disease
Speaker: Nico Diederich (Luxembourg)
Roundtable: Meet the Experts
Level of
talks: Crosstalk
Note: Seats at tables
are limited. Ticket required.
Table 1: Speech Pathology and Parkinson’s
Host: Lorraine Ramig (USA)
Table 2: Physical therapy and Parkinson’s - can it really
help?
Host: Terry
Ellis (USA)
Table
3: Blogging and Parkinson's:
How people with Parkinson's can educate and raise awareness via blogging
Co-hosts: Bob Kuhn
(Canada) & Jean Burns (USA)
Table 4: What to Ask Before Joining a Clinical Trial: PwP
to PwP
Co-hosts: Jon Stamford
(UK) & Israel Robledo (USA)
Table
5: Young Onset Parkinson’s: Unique
Challenges
Host: Peter Davison
(Canada)
Table 6: Psychiatric Changes in Parkinson's Disease
Host: Laura Marsh (USA)
Table 7: Sex & Parkinson's disease
Host: Gila Bronner (Israel)
Table 8: What's in the pipeline for new delivery systems for Parkinson's?
Host: Angelo Antonini (Italy)
Table 9: Facing your fear: Rising to the Challenge
Host: Alex Flynn (UK)
Wrap-Up 5:15PM – 6:30PM
Facilitator:
David
Iverson (USA)
Panelists: Ted Dawson (USA), Andres Lozano (Canada), Jeffrey Kordower (USA),
Mark Guttman (Canada), Susan Fox (Canada)
THURSDAY, OCTOBER 3, 2013
Day 2:
Non-motor manifestations
of Parkinson’s disease
Plenary Session 
Level of
talks: Crosstalk
Learning
Objectives:
1. Better understand the
diversity of non-motor symptoms that can be present in PD and analyze their clinical
features;
2. Recognize the role of imaging studies in the assessment and understanding of
non-motor manifestations of PD;
3. Be able to describe how co-existent medical conditions or co-morbidities may
have an impact on the clinical features and the progression of PD.
Chair:
Oscar Gershanik (Argentina)
Co-chair: Sharon Daborn (Australia)
Lecture
1:
The spectrum of non-motor symptoms in PD
Speaker: Ray Chaudhuri
(UK)
Lecture 2: Dementia and psychiatric
manifestations in PD
Speaker: David Burn
(UK)
Lecture 3: Contribution
of functional neuroimaging to the understanding of non-motor manifestations of
PD
Speaker:
Antonio
Strafella, (Canada)
Lecture
4:
The impact of other medical conditions on the course of PD
Speaker:
Janis
Miyasaki (Canada)
WPC James Parkinson Lecture
Introduction by: Jon Stoessl (Canada)
Presentation Title: Past, Present and Future of Parkinson Disease
Speaker: Warren Olanow (USA)
SESSION I -- 1:30PM - 3:00PM
Parallel Session: PD or not PD - that is the question: Is it
time to redefine/reclassify Parkinson’s disease?
Level
of talks: Crosstalk
Learning
Objectives:
1. Discuss the
current definitions and diagnostic criteria for PD and the reasons for
redefining the disorder;
2. Discuss
"prodromal" Parkinson's disease and monogenetic Parkinson's disease
and how these challenge approaches to classification and diagnosis;
3. Discuss
considerations and challenges to establishing new diagnostic criteria for PD.
Chair:
Christopher Goetz (USA)
Co-chair: Daniela Berg (Germany)
Lecture 1: Current definitions and diagnostic criteria: reasons for redefining the
disorder.
Speaker: Joaquim
Ferreira (Portugal)
Lecture
2: The challenge of "prodromal" Parkinson's disease
Speaker: Ron
Postuma (Canada)
Lecture 3: Redefining Parkinson's
disease: possible approaches to developing new diagnostic criteria
Speaker: Daniela
Berg (Germany)
Parallel Session: Hallucinations
and related phenomena in PD
Level of
talks: Crosstalk
Learning
Objectives:
1. Participants
should be able to describe the range of psychotic phenomenon in PD;
2. Identification
of factors associated with the pathogenesis and progression of PD psychosis;
3. Discuss evidence
based medicine recommendations and integrated treatment options in the
management of PD psychosis.
Chair: Ronald Pfeiffer
(USA)
Co-chair: Regina Katzenschlager (Austria)
Lecture
1:
Prototypical and less common hallucinations
Speaker: Regina
Katzenschlager (Austria)
Lecture 2: Where is the nucleus hallucinatorius and how it gets stimulated?
Speaker: Nico Diederich (Luxembourg)
Lecture 3: Management of hallucinations and related symptoms
Speaker: Gilles Fénelon (France)
Parallel Session: Mitochondrial quality control mechanisms
Level of
talks: Highly scientific
Learning Objectives:
1. Understand the
surveillance mechanisms acting at the molecular, organelle, and cellular levels
that monitor mitochondrial integrity and ensure the maintenance of
mitochondrial proteostasis;
2. Identify the
molecular mechanisms by which Pink1 and Parkin regulate the selective removal
of impaired mitochondria by autophagy;
3. Recognize the
molecular machinery responsible for mitochondrial fusion/fission and cristae
morphology and understand how alterations in these pathways can impair mitochondrial
trafficking and distribution and lead to neurodegeneration.
Chair: Edward Fon (Canada)
Co-chair: Charleen Chu (USA)
Lecture
1: Mitochondrial quality control- a matter of life and death for neurons
Speaker: Heidi M.
McBride (Canada)
Lecture 2: Mechanisms of mitophagy in Parkinson’s disease
Speaker: Charleen Chu (USA)
Lecture
3: Mitochondrial remodeling in the control of apoptosis
Speaker: Luca Scorrano
(Switzerland)
Parallel Session: Ways for people with Parkinson’s to become
empowered
Level
of talks: Crosstalk
Learning Objectives:
1.
To provide a broad perspective on different aspects
and definitions of "patient empowerment” explaining what it really means to be
empowered;
2.
Understand ways that empowered patients can inform
the body of knowledge on what it’s like living with a chronic disease and how
this influence matters;
3.
Understand ways how patient empowerment can be
achieved.
Chair: Joyce Gordon
(Canada)
Co-chair: Fulvio Capitanio (Spain)
Lecture
1: Why and how people with Parkinson’s need empowerment - Finding your own
niche
Speaker:
Fulvio
Capitanio (Spain)
Lecture
2:
Evidence-based self-management practices
Speaker:
Patrick
McGowan (Canada)
Lecture 3: Increasing Parkinson’s advocacy effectiveness with
lessons learned from other diseases
Speaker: Dave de Bronkhart (USA)
Workshop: Benefits and risks of genetic testing
Level of
talks: Crosstalk
Learning
Objectives:
1.
To learn about the different techniques and
resources available to test for genetic defects;
2.
To understand the implications of knowing and
not-knowing that one carries a mutation;
3.
To appreciate who and when might benefit from
genetic testing.
Introduction: Overview of genetic
testing
Speaker: Oksana Suchowersky
(Canada)
Case
Presentations:
Panelists: Oksana Suchowersky
(Canada), Susan Bressman (USA), Nathalie Bolduc (Canada)
Workshop: Sleep and fatigue in PD
Level of talks: Crosstalk
Learning
Objectives:
1. To review the
epidemiology and natural history of sleep disorders and fatigue in PD;
2. To review
validated tools for measuring fatigue and diagnosing sleep disorders;
3.
To review possible treatment modalities, both
pharmacological and non-pharmacological.
Introduction: Overview of sleep,
sleepiness and fatigue in PD
Speaker: Joseph H Friedman (USA)
Case
Presentations: Tips to dealing with sleeplessness and fatigue
Panelists: Joseph Friedman (USA) and
Cathi A. Thomas (USA)
Workshop: Ethical dilemmas posed by new
diagnostic and therapeutic technologies
Level
of talks: Crosstalk
Learning Objectives
1.
To acquire the basis of ethics;
2. To
learn, through case presentations, about the types of ethical issues;
3. To
better understand rational justification for ethical decisions.
Introduction: Overview of ethics
in medicine
Speaker: John Loike (USA)
Panel
discussion:
Panelists: John Loike (USA), Hubert
Fernandez (USA), Jon Stamford (UK) and Karl Friedl (USA)
Workshop: Tricks of the trade: clever strategies to improve mobility
Level
of talks: Crosstalk
Learning Objectives:
1.
Explore clever strategies to overcome challenges to
daily mobility (suggestions from professional and PWPs);
2.
Demonstrate the integration of strategies to
improve mobility into daily life (videos, live demonstrations);
3.
Discuss potential mechanisms underlying strategy
effectiveness.
Introduction: Overview of Idea
Behind Strategies for improving mobility
Speaker: Terry Ellis (USA)
Panel discussion:
Panelists: Terry Ellis (USA), Mariella
Graziano (Luxembourg), Samyra Keus (Netherlands), Pam Quinn (USA)
French Track
(Learn more about the french track)
Level of talks: Crosstalk in French
Chair: Michel Panisset (Canada)
Lecture 1: Advances in the genetics of
Parkinson’s disease
Speaker: Nicolas Dupré
(Canada)
Lecture 2: The experimental models of
Parkinson’s disease: Are they useful?
Speaker: Marie-Francoise
Chesselet (USA)
SESSION II - 3:30PM-
5:00PM
Parallel Session: PD or look-alikes: how to diagnose them and
what are their long-term prognoses?
Level of
talks: Crosstalk
Learning
Objectives:
1. To learn how to
diagnose and differentiate drug-induced parkinsonism from PD and discuss its
long-term prognosis;
2. To learn how to
diagnose and differentiate progressive supranuclear palsy from PD and discuss its
long-term prognosis;
3. To learn how to
diagnose and differentiate multiple system atrophy from PD and discuss its
long-term prognosis.
Chair:
Joseph Jankovic (USA)
Co-chair: Irene Litvan (USA)
Lecture 1: Drug Induced Parkinsonism
Speaker:
Stewart
Factor (USA)
Lecture
2: PD or progressive supranuclear palsy
Speaker:
Irene
Litvan (USA)
Lecture
3: PD or Multiple system atrophy
Speaker:
Cheryl
Waters (USA)
Parallel Session: Clinical trial outcomes—What do they really
mean?
Level
of talks: Moderately scientific
Learning Objectives:
1.
Understand the complexities of measuring outcomes
of clinical trials;
2.
Be familiar current trials for PD;
3.
Learn about the placebo effect and its consequences
on clinical trials.
Chair: Olivier Rascol
(France)
Co-Chair: Cristina Sampaio (USA)
Lecture 1: Clinical trial endpoints in PD – What is really meaningful?
Speaker:
Cristina
Sampaio (USA)
Lecture
2:
The placebo effect: how it complicates clinical trial results
Speaker: Christopher Goetz (USA)
Lecture
3:
Slowing clinical progression in PD –can it be proven in clinical trials?
Speaker: Fabrizio
Stocchi (Italy)
Parallel Session: The search for new delivery methods for
drugs
Level
of talks: Crosstalk
Learning Objectives:
1.
Understand the relevance of continuous drug
delivery for PD;
2.
Become familiar with recent developments in the
field of oral and non-oral drug delivery;
3.
Critically discuss the potential role of gene
therapy in the field of PD.
Chair:
David Brooks (UK)
Co-chair: Anthony Schapira (UK)
Lecture 1: Improving oral drug delivery in PD – recent advances
Speaker: Anthony Schapira (UK)
Lecture
2:
Infusion therapies and other non-oral routes of drug delivery
Speaker: Angelo Antonini (Italy)
Lecture 3: Delivering therapeutic
genes into the brain – a future way of drug delivery?
Speaker: Stephane Palfi (France)
Parallel Session: Is PD an axonopathy?
Level
of talks: Highly scientific
Learning
Objectives:
1. Understand the
pathological findings supporting the presence of axonopathy in PD;
2. Understand
evidence for primary synaptic pathology in PD and its implication for
treatment;
3. Understand
evidence and implications for altered axonal transport in PD.
Chair:
Maria Spillantini (UK)
Co-chair: Sreegana Chandra (USA)
Lecture 1: Pathological evidence for axonopathy in Parkinson’s disease
Speaker: Dennis Dickson (USA)
Lecture
2: Evidence for synaptic dysfunction in Parkinson’s disease
Speaker: Sreegana
Chandra (USA)
Lecture
3:
Alterations in axonal transport in Parkinson’s disease
Speaker: Scott Brady
(USA)
Workshop: Choosing
a care facility: When is it time? What are the options?
Level of
talks: Crosstalk
Learning
Objectives:
1. Learn when it is time to consider a care facility
and what are the alternatives;
2. Explore models of informed care from around the
world that maximize comfort, care and activity for Parkinson patients;
3. Learn the challenges and successful approaches used
to advocate for systems that meet the specific needs of PD patients.
Introduction: Overview of
Care Models and Options
Speaker: Elaine Book
(Canada)
Case
Presentation: Global Care Models
Panelists: Maria Barretto
(India), Marten Munneke (Netherlands), Meg Morris (Australia), Ruth Hagestuen (USA)
Workshop: Do experimental models of Parkinson’s disease predict
treatment outcome?
Level of talks: Moderately scientific
Learning objectives:
1.
To learn about the main experimental models of PD;
2.
To understand the key challenges between the
preclinical and clinical studies;
3.
To participate in a discussion about potential
remedy.
Overview:
Speaker: Anthony Lang (Canada)
Panel discussion:
Panelists:
Anthony Lang (Canada), Serge Przedborski (USA), Etienne Hirsch (France),
Ted Dawson (USA)
Workshop: Complementary and integrative medicine
Level
of talks: Crosstalk
Learning
objectives:
1.
Learn about the fields of alternative,
complementary and integrative medicines;
2.
Recognize the art and the science of these
therapies;
3.
Understand the categories of integrative medicine/complementary
and alternative medicines, including a discussion of the scientific evidence,
the risks, the potential benefits and the future of those therapies most
commonly used by the PD community.
Introduction: Insights into
Complementary Therapies
Speaker:
Monique
Giroux (USA)
Panel
discussion: The Art and the Science of Complementary Therapies
Panelists: Monique Giroux (USA), Louis Tan (Singapore), Angela Robb (USA)
Workshop: Dance and Parkinson’s: Why and How?
Level
of talks: Crosstalk
Learning
Objectives:
1.
Describe the research evidence supporting the
benefits of dance in PD;
2.
Describe the essential elements of dance thought to
mediate improvements in function;
3.
Discuss ways to incorporate dance into your life:
community based models
Overview: How do we know
dance helps people with Parkinson’s?
Speaker: Gammon Earhart
(USA)
Panel
discussion: Let’s dance! Showing the results of movement
Panelists:
Gammon
Earhart (USA), David Leventhal (USA),
Maura Fisher (Canada), JoanAbbey Sack (Canada), Diane Côté (Canada)
French Track
(Learn more about the french track)
Level of talks: Crosstalk in French
Chair: Anne-Louise Lafontaine (Canada)
Lecture 1: The problem of the accumulation
of toxic proteins and the significance of the quality control mechanisms in
Parkinson’s disease
Speaker: Edward Fon (Canada)
Lecture 2: Non-motor manifestations of Parkinson’s disease
Speaker: Sylvain Chouinard
(Canada)
Roundtable: Meet the Experts
Level
of talks: Crosstalk
Table 1: DBS: A Team Effort
Co-hosts: Elena Moro
(France) & David Simmonds (Canada)
Table 2: Effective
Fundraising Models for PwP founded non-profit organizations: How to survive
Hosts: Fulvio
Capitanio (Spain) & Tom Isaacs (UK)
Table 3: Non-motor Symptoms & PD
Host: Ronald Pfeiffer (USA)
Table
4: Genetic Testing & PD: What questions you should be asking
Host: Susan
Bressman (USA)
Table
5: Parkinson’s disease and cancer
(repeated on Friday)
Host: Rivka Inzelberg (Israel)
Table 6: Staying engaged and raising children after a
Parkinson’s diagnosis
Co-hosts: Soania Mathur (Canada) & Sharon Daborn
(Australia)
Table
7: Parkinson’s disease &
women
Co-hosts: Claire Henchcliffe (USA) & Sara Riggare
(Sweden)
Table 8: Flying solo - living alone with Parkinson's
Co-hosts: Ryan Tripp (Canada) & Cathi Thomas (USA)
Table 9: Service dogs and Parkinson's: Everything you need to know
Co-hosts: Carolyn Weaver (USA) & Renee Le Verrier (USA)
Wrap-Up 5:15PM – 6:30PM
Facilitator:
David
Iverson (USA)
Panelists:
Anthony
Lang (Canada), Kapil Sethi (USA), Joseph H Friedman (USA), Janis Miyasaki
(Canada), David Brooks (UK), Alex Tröster (USA)
Friday, October 4, 2013
Day 3:
New Views on
the Management of Parkinson’s disease
Plenary Session
Level of
talks: Crosstalk
Learning Objectives:
1. Appreciate the
experimental developments and current clinical applications of cell and gene-based
technologies;
2. Learn about non-medical
interventions, including lifestyle activities, self-management and empowerment
aspects;
3. Understand the pros and
cons of a multidisciplinary treatment approach.
Chair:
Eduardo Tolosa (Spain)
Co-Chair: Alice Templin (Canada)
Lecture 1: Cell and gene-based technologies for restorative
and neuroprotective therapies
Speaker: Roger Barker (UK)
Lecture 2: Exercise, diet, and other lifestyle activities as
treatments for Parkinson disease
Speaker:
Marten
Munneke (Netherlands)
Lecture 3: Empowered patients and how they can help improve
healthcare.
Speaker: Dave de Bronkhart (USA)
Lecture 4: Roles for healthcare professionals:
multidisciplinary care for Parkinson disease.
Speaker: Nir Giladi (Israel)
Special Lecture: Living Positively After a Diagnosis of
Parkinson's
Introduction by: Robin Elliott (USA)
Speaker: Rich Clifford (USA), Soania Mathur (Canada) & Alex Flynn (UK)
SESSION I – 1:30PM – 3:00PM
Parallel Session: Update on Gaucher and Parkinson's diseases
Level
of talks: Crosstalk
Learning Objectives:
1. Understand
the connection between mutations that cause Gaucher disease and PD;
2. To
acquire knowledge about the link between Gaucher’s disease and
synucleinopathies;
3.
To understand how treatments developed for Gaucher disease may be beneficial in
PD.
Chair: Susan Bressman
(USA)
Co-chair: Pablo Sardi (USA)
Lecture 1:
What is new about the link between Gaucher mutations and Parkinsonism
Speaker: Roy Alcalay (USA)
Lecture 2: Exploring mechanisms that underlie between mutations in Gaucher disease gene and synucleinopathy risk
Speaker: Michael
Schlossmacher (Canada)
Lecture
3: How the understanding of Gaucher could lead to new therapies for
Parkinson's
Speaker: Pablo Sardi (USA)
Parallel Session: New insights
into Parkinson's disease from experimental cell- and gene-based strategies
Level of talks: Highly
Scientific
Learning Objectives:
1. Learn about
recent developments in the use of human embryonic stem cells, and induced
pluripotent stem cells, to generated dopamine neurons for cell replacement in
PD;
2. Learn about two
novel strategies to modify disease progression in PD based on insights in
neurotrophic factor signalling;
3. Learn about the
role of the role of the developmental transcription factor Nurr1 as a mediator
of neurodegeneration in PD.
Chair: Roger Barker (UK)
Co-chair: Mickael Decressac (Sweden)
Lecture 1: Use of human ES and iPS cells for cell replacement in
Parkinson´s disease.
Speaker: Malin Parmar (Sweden)
Lecture
2:
Role of Sonic hedgehog in maintaining striatal homeostasis
Speaker: Andreas Kottmann (USA)
Lecture 3: Nurr1 as a therapeutic
target for neuroprotection and disease modification in PD
Speaker:
Mickael Decressac (Sweden)
Parallel Session: Neurobiology and treatment of dyskinesias
Level of
talks: Moderately scientific
Learning Objectives:
1. Increase the
knowledge on the various neurotransmitters implicated in L-DOPA induced
dyskinesia describing their possible interactions;
2. Provide a broad
perspective of the novel therapeutic strategies emerging from preclinical
studies utilizing experimental models of PD;
3. Increase the
understanding of the role of both short and long term synaptic mechanisms
implicated in the motor and behavioral complications of chronic L-DOPA therapy.
Chair: Paolo Calabresi
(Italy)
Co-chair: Erwan Bezard (France)
Lecture
1:
Maladaptive plasticity in L-DOPA-induced dyskinesia: emerging role of serotonin
transmission and other presynaptic factors
Speaker: Angela M.
Cenci (Sweden)
Lecture
2:
Pre- and post-synaptic molecular mechanism underlying L-DOPA-induced dyskinesia
as possible new pharmacological targets
Speaker:
Erwan
Bezard (France)
Lecture
3:
Multiple dopamine-dependent synaptic mechanisms underlying dyskinesia in animal
models
Speaker:
Barbara
Picconi (Italy)
Parallel Session: Pathophysiology and management of head drop and bent spine
in PD: Are they dystonia or myopathy or both?
Level of
talks: Moderately scientific
Learning objectives:
1. To
learn current understanding of the mechanism of dropped head and bent back in
PD
2. To
learn how to differentiate similar condition with different etiology
3. To learn
current management of dropped head and bent back
Chair: Ryuji
Kaji (Japan)
Co-chair: Simone
Spuler (Germany)
Lecture 1: Myopathy
causing camptocormia in idiopathic Parkinson's disease
Speaker: Simone
Spuler (Germany)
Lecture 2:
Camptocormia: pathogenesis, classification, and response to therapy
Speaker: Joseph Jankovic (USA)
Lecture 3: Dropped head syndrome in Parkinson's disease
Speaker: Kenichi Kashihara (Japan)
Workshop: What you need to
know about DBS: Selection, side effects, and new device development
Level
of talks: Moderately scientific
Learning objectives:
1. To provide an
interactive educational program focusing on the latest advances in and the
practical aspects of deep brain stimulation for Parkinson’s disease;
2. To discuss
rationale for selection of patients, targets, devices, and stimulation
parameters;
3. To review the
potential risks and how to minimize the potential long-term effects and
complications related to deep brain stimulation.
Overview:
Deep brain stimulation
Speaker:
Michael
Okun (USA)
Case
presentations
Panelists: Michael Okun (USA) and Elena Moro (France)
Workshop: Is PD an accelerated form of aging?
Level
of talks: Crosstalk
Learning Objectives:
1. To learn the
selective vulnerabilities seen in PD and normal aging;
2. To understand
the function and electrophysiological changes seen in PD and normal aging;
3. To be able to
discuss new models of normal aging and illustrate their relevance to PD.
Overview: Aging and
PD
Speaker: Timothy J. Collier (USA)
Panel discussion: The implication of
cell function in determining differential vulnerabilities
Panelists: Jeffrey
Kordower (USA), James Surmeier (USA) and Timothy Collier (USA)
Workshop: Pain in PD
Level of talks: Crosstalk
Learning Objectives:
1. To gain an
understanding of the multifaceted nature of pain syndromes in PD;
2. To understand
the neurophysiological substrate of pain in PD;
3. To develop a
practical approach to the management of pain in PD.
Overview: Pain in PD
Speaker: Blair Ford (USA)
Panel
discussion: A practical and clinical approach
to treating pain in PD
Panelists:
David
Lussier (Canada) and Blair Ford (USA)
Workshop: Speech and
Parkinson’s
Level of talks: Crosstalk
Learning objectives:
1. To gain an
understanding of the complex skills needed for effective speech production as
shown through recent evidence;
2. Understand the
best approaches to deal with the voice, speech, and language changes of PD over
the course of the illness and most effective interventions;
3. To learn best
practice Speech Language Pathology interventions and options for treatment in
the early, middle and late stages of Parkinson’s.
Overview: Models of care on speech for people with Parkinson’s
Speaker: Angie Roberts-South (Canada)
Case Presentations:
Panelists: Angie Roberts-South
(Canada), Lorraine Ramig (USA) & Bonnie Bereskin (Canada)
French Track
(Learn more about the french track)
Level of talks: Crosstalk in French
Chair: Sylvain Chouinard (Canada)
Lecture 1: Is there a link between
Parkinson’s disease and the Gaucher metabolic disorder?
Speaker: Guy Rouleau (Canada)
Lecture 2: How imaging technologies can
inform about the brain function in Parkinsonian patients
Speaker: Alain Dagher (Canada)
SESSION II – 3:30 – 5:00PM
Parallel Session: Freezing and falls
Level of
talks: Crosstalk
Learning Objectives:
1. Describe the
potential mechanisms underlying freezing of gait and the role of cueing in
reducing freezing;
2. Describe the
mechanisms underlying falling and the evidence on the modifiability of postural
control deficits in PD;
3. Discuss the
evidence on the benefits of exercise in reducing falling in PD.
Chair: Nir Giladi (Israel)
Co-chair: Alice Nieuwboer (Belgium)
Lecture
1:
Freezing- Underlying mechanisms and the role of cueing
Speaker:
Alice
Nieuwboer (Belgium)
Lecture
2:
Why do persons with PD fall? Does treatment help to reduce falling?
Speaker:
Fay
Horak (USA)
Lecture
3: The benefits of exercise in reducing falling in PD
Speaker: Victoria
Goodwin (UK)
Parallel Session: Promising approaches to identify and
validate biomarkers
Level of talks: Crosstalk
Learning Objectives:
1.
To learn about disease signatures and markers;
2.
To appreciate the array of techniques available to
search for biomarkers;
3.
To be informed about new and promising biomarkers
for PD.
Chair: Kapil Sethi (USA)
Co-chair:
David Standaert (USA)
Lecture
1:
What are biomarkers and why do we need them?
Speaker: David Standaert (USA)
Lecture
2: Update on unbiased methodologies to identify biomarkers
Speaker: Howard
Federoff (USA)
Lecture
3:
Emerging biomarkers
Speaker: Claire Henchcliffe (USA)
Parallel Session: Drug development challenges: from the
pharmaceutical industry, regulatory agencies, and patient protection
organizations perspective
Level
of talks: Crosstalk
Learning Objectives:
1.
To understand the challenges to drug development
from a variety of perspectives;
2.
Appreciate the difficult course of drug development
from bench to bedside;
3.
Understand the role of protection agencies in drug
development.
Chair: Baltazar Gomez-Mancilla
(Switzerland)
Co-chair: TBD
Lecture
1: Drug development challenges-Pharmaceutical industry perspective
Speaker:
Bernard
Ravina (USA)
Lecture 2: Drug development challenges - A regulatory perspective
Speaker: TBD
Lecture
3:
Drug development challenges-Patient protection agency perspective
Speaker: TBD
Parallel Session: How should levodopa induced dyskinesia be
managed today?
Level
of talks: Crosstalk
Learning objectives:
1.
To understand the subtypes of levodopa induced
dyskinesias (LID) in Parkinson Disease (PD);
2.
Be able to evaluate and assess severity of
dyskinesia in patients with LID;
3.
Understand how to prevent and manage
levodopa-induced dyskinesia.
Chair: Kailash Bhatia (UK)
Co-chair: Jose Obeso (Spain)
Lecture
1:
Recognizing the subtypes and assessing severity of dyskinesia and the clinical
impact
Speaker:
Beom S. Jeon (South Korea)
Lecture
2: Current management of LID – medical and surgical
Speaker:
Jose
Obeso (Spain)
Lecture 3: Future
Management of LID: What’s in the pipeline?
Speaker: Susan Fox (Canada)
Workshop: The role of people with Parkinson's in the research process:
How are they prepared and what can they do?
Level of talks: Crosstalk
Learning Objectives:
1.
To understand how engaging people with Parkinson's
informs the research process;
2.
Be able to list ways to engage PwPs in the research
process;
3.
Understand how to improve communication between
researchers and research participants in clinical trials.
Introduction: Overview of the research
process and advances in communication between researchers and participants
Speaker: Diane Cook (USA)
Panel
discussion:
Panelists: Benzi Kluger
(USA) (Researcher), Diane Cook (USA), Veronica Todaro (USA), Claire Meunier
(USA)
Workshop: Which physical and mental exercises are good for people with
Parkinson’s?
Level of
talks: Crosstalk
Learning objectives:
1.
Understand the physiological and scientific basis
for physical and cognitive rehabilitation in Parkinson’s disease;
2.
Learn the different modalities of physical and
cognitive rehabilitation in Parkinson’s disease reviewing the evidence from
clinical trials;
3.
Understand the role of neuropsychologists, exercise
trainers, and physical therapists in the management of Parkinson’s disease.
Overview: Exercise,
physical therapy, and benefits to the brain of Parkinson’s patients
Speaker: Lynn Rochester (UK)
Panel discussion: An active mind for
a healthier life with Parkinson’s: case studies
Panelists: Lynn Rochester (UK) and Terry Ellis (USA)
Workshop: Parkinson's and Mood Changes: Depression, Apathy and Anxiety
Level of talks: Crosstalk
Learning Objectives:
1.
Recognize the common behavioral changes seen in
anxiety and depressive disturbances in PD;
2.
List features that distinguish anxiety and
depressive disturbances from healthy affective changes;
3.
Identify methods to treat and manage depression, apathy,
and anxiety in PD.
Overview: Depression, apathy and anxiety in Parkinson’s disease
Speaker: Laura Marsh (USA)
Panel
discussion: Clinical Features and Treatment for Depression and Anxiety in
Parkinson’s Disease
Panelists: Roseanne Dobkin (USA) and
Laura Marsh (USA)
French Track
(Learn more about the french track)
Level of talks: Crosstalk in French
Chair: Pierre
Blanchet (Canada)
Lecture 1: Dyskinesias: Mechanism and
Treatment
Speaker: Erwan Bezard (France)
Lecture 2: Parkinson’s disease is much more
than a disease of dopamine
Speaker: Etienne Hirsch (France)
Roundtable: Meet the Experts
Level of talks: Crosstalk
Table 1: How can
occupational therapists help manage memory challenges?
Host:
Margarita Makoutonina (Australia)
Table 2: Motor fluctuations & dyskinesias
Host: Joseph Jankovic (USA)
Table 3: Speech and
PD
Host: Angie Roberts-South
(Canada)
Table 4: Non-motor Symptoms & PD
Host: Ray Chaudhuri (UK)
Table 5: Issues specific to Adolescents of Parents with
Parkinson's
Host: Elaine Book (Canada)
Table 6: What are animal models, why
are they important in PD research and what are the challenges of using them?
Host: Marie-Francoise Chesselet
(USA)
Table
7: Parkinson’s disease and cancer
Host: Rivka Inzelberg (Israel)
Table 8: Open Discussion on Parkinson’s
disease and the WPC
Co-hosts: Stanley Fahn (USA) & Jon Stoessl (Canada)
Table
9: Deep Brain Stimulation
Host: Michael Okun (USA)
Wrap-Up: 5:15PM – 6:30PM
Facilitator:
David
Iverson (USA)
Panelists:
Terry
Ellis (USA), Eduardo Tolosa (Spain), Howard Federoff (USA), Blair Ford (USA), Khailash
Bhatia (UK)
Print to Page
